Entrada Therapeutics Stock Probability of Future Stock Price Finishing Over 14.45
| TRDA Stock | USD 17.41 0.33 1.86% |
Entrada |
Entrada Therapeutics Target Price Odds to finish over 14.45
The tendency of Entrada Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 14.45 in 90 days |
| 17.41 | 90 days | 14.45 | close to 99 |
Based on a normal probability distribution, the odds of Entrada Therapeutics to stay above $ 14.45 in 90 days from now is close to 99 (This Entrada Therapeutics probability density function shows the probability of Entrada Stock to fall within a particular range of prices over 90 days) . Probability of Entrada Therapeutics price to stay between $ 14.45 and its current price of $17.41 at the end of the 90-day period is about 33.55 .
Given the investment horizon of 90 days Entrada Therapeutics has a beta of 0.51. This usually implies as returns on the market go up, Entrada Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Entrada Therapeutics will be expected to be much smaller as well. Additionally Entrada Therapeutics has an alpha of 0.2423, implying that it can generate a 0.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Entrada Therapeutics Price Density |
| Price |
Predictive Modules for Entrada Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entrada Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entrada Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entrada Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Entrada Therapeutics is not an exception. The market had few large corrections towards the Entrada Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entrada Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entrada Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | 0.51 | |
σ | Overall volatility | 1.46 | |
Ir | Information ratio | 0.08 |
Entrada Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entrada Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entrada Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entrada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Entrada Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Entrada Stock often depends not only on the future outlook of the current and potential Entrada Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Entrada Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.1 M | |
| Cash And Short Term Investments | 352 M |
Entrada Therapeutics Technical Analysis
Entrada Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Entrada Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Entrada Therapeutics. In general, you should focus on analyzing Entrada Stock price patterns and their correlations with different microeconomic environments and drivers.
Entrada Therapeutics Predictive Forecast Models
Entrada Therapeutics' time-series forecasting models is one of many Entrada Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Entrada Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Entrada Therapeutics
Checking the ongoing alerts about Entrada Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Entrada Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entrada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Check out Entrada Therapeutics Backtesting, Entrada Therapeutics Valuation, Entrada Therapeutics Correlation, Entrada Therapeutics Hype Analysis, Entrada Therapeutics Volatility, Entrada Therapeutics History as well as Entrada Therapeutics Performance. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.